Last updated 2026-06-18
- Raised $4M funding round, Dec 2023
- Raised $700k funding round, Jul 2023
- Raised $750k funding round, Nov 2022
Total raised
$6.5M
Last: 2023-12
Stage
Seed
Founded
2017
Headcount
7
HQ
Nesher, Israel
Sector
Health Tech & Life Sciences
About
AnserBio (previously ExoProTher Medical) is a biomedical start-up developing a novel approach to cancer treatment. The company targets the p53-based tumor suppression mechanism that is mutated in over 60% of cancers, including glioblastoma, colon, bladder, ovarian, and small cell lung cancers. It uses proprietary cell derived nano-particles to deliver healthy p53 and restore the body's natural tumor suppression function with minimal adverse side effects.
The company is in the preclinical stage.
Funding history · 6 rounds · $6.5M total
2023-12
$4.0M
2023-07
$700K
2022-11
$750K
2021-12
$750K
2021-01
$250K
2020-01
Undisclosed
Q&A
- What is AnserBio's primary focus?
- AnserBio is a biomedical startup developing a novel approach to cancer treatment, specifically targeting the p53-based tumor suppression mechanism that is mutated in over 60% of cancers.
- What technology does AnserBio utilize for its cancer treatment?
- AnserBio uses proprietary cell-derived nanoparticles to deliver healthy p53 protein, aiming to restore the body's natural tumor suppression function.
- When was AnserBio founded?
- AnserBio was founded in January 2017.
- What is AnserBio's current employee count?
- AnserBio has 7 employees, which falls into the 1-10 employee bucket.
- What is the total amount of funding AnserBio has raised to date?
- AnserBio has raised a total of $6,450,000 USD.
- When did AnserBio complete its most recent funding round and for what amount?
- AnserBio completed a funding round in December 2023, raising $4,000,000 USD.
- Which investors participated in AnserBio's July 2023 funding round?
- Peregrine Ventures participated in AnserBio's funding round in July 2023.
- Who are the co-founders of AnserBio?
- The co-founders of AnserBio are Lana Volokh, who serves as CEO, and Dr. Alex Tendler, who serves as CTO.
- What is AnserBio's current product development stage?
- AnserBio is currently in the preclinical stage of product development.
Team · 2
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Materials & SubstancesNanomaterialsBiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
biotechnologymedical-technologiestherapeuticsoncologycancercell-therapynanotechnology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | anser-bio.com |
|---|---|
| linkedin.com/company/27192102 | |
| facebook.com/ExoProTher |
Identifiers & details
| Former names | ExoProTher Medical |
|---|---|
| Founded | 2017-1 |
| Employees (exact) | 7 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | anser-bio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|